Last updated on July 2008

Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma


Brief description of study

To evaluate the complete clinical response rate according to the International Working Group criteria with a consolidation treatment with 90Y-ibritumomab tiuxetan (Zevalin®) in patients with high-risk follicular lymphoma with either partial or complete response to R-CHOP induction chemotherapy

Clinical Study Identifier: NCT00722930

Contact Investigators or Research Sites near you

Start Over

Mariano Provencio, MD

Hospital Universitario Virgen Macarena
Sevilla, Spain
  Connect »